Biosimilar Battlefield: U.S. Humira Pushed to 2023
We are updating our market model to reflect the patent litigation settlement between Amgen Inc (AMGN US) and Abbvie Inc (ABBV US) , the...
661 Views
Celltrion's KOSPI Move - Seo Jung-Jin, Temasek & Price Predictions
The big day (KOSPI move decision day) is tomorrow (Sep 29) for Celltrion Inc (068270 KS). At this point, many are thinking that Celltrion's KOSPI...
385 Views
The Week That Was in NorthAsia@Smartkarma: Sep24
It has been another week in North Asia. North Korean missile/nuclear tests and threats? Check. Trump rhetoric on North Korea and football players?...
315 Views
Biosimilar Battlefield: Celltrion Forecasts
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
594 Views
TissueGene IPO Part 1 - IPO Prospectus Summary
What is Korea's hottest stock now? I guess many investors will have SillaJen, Inc. (0908477D KS) in their mind when asked this question. SillaJen's...
816 Views